![](/wp-content/uploads/2018/10/flyZmjEzSJqf9Cv9bkVk.png)
$599
Semaglutide Ph3 Obesity Positive Topline Results (STEP 4)
Yesterday, Novo Nordisk announced positive results from the Ph3a STEP 4 trial evaluating the safety and efficacy of Semaglutide 2.4mg on body weight. Recall, STEP 4 is the first of the Ph3 semaglutide obesity program trials to read out. Below, FENIX provides an overview of the results as well as thoughts on potential readthrough to high-dose Ozempic.